WO1999021540B1 - Method of reducing craving in mammals - Google Patents

Method of reducing craving in mammals

Info

Publication number
WO1999021540B1
WO1999021540B1 PCT/US1998/022255 US9822255W WO9921540B1 WO 1999021540 B1 WO1999021540 B1 WO 1999021540B1 US 9822255 W US9822255 W US 9822255W WO 9921540 B1 WO9921540 B1 WO 9921540B1
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
compound
sibutramine
mammal
beta
Prior art date
Application number
PCT/US1998/022255
Other languages
French (fr)
Other versions
WO1999021540A2 (en
WO1999021540A3 (en
Inventor
Vicki Coffin
Paul W Glue
Original Assignee
Schering Corp
Vicki Coffin
Paul W Glue
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0100115A priority Critical patent/HUP0100115A2/en
Application filed by Schering Corp, Vicki Coffin, Paul W Glue filed Critical Schering Corp
Priority to AU11100/99A priority patent/AU1110099A/en
Priority to BR9814830-3A priority patent/BR9814830A/en
Priority to EP98953826A priority patent/EP1043980A2/en
Priority to CA002308453A priority patent/CA2308453A1/en
Priority to JP2000517699A priority patent/JP2001520989A/en
Priority to SK581-2000A priority patent/SK5812000A3/en
Priority to IL13565998A priority patent/IL135659A0/en
Priority to KR1020007004505A priority patent/KR20010031470A/en
Publication of WO1999021540A2 publication Critical patent/WO1999021540A2/en
Publication of WO1999021540A3 publication Critical patent/WO1999021540A3/en
Publication of WO1999021540B1 publication Critical patent/WO1999021540B1/en
Priority to NO20002149A priority patent/NO20002149L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of reducing craving in a mammal to food or an addictive substance is disclosed. The method comprises administering to the mammal an effective amount of a D1/D5 antagonist or a D1/D5 partial agonist alone or in combination with other specified CNS compounds.

Claims

- 18 -
AMENDED CLAIMS
[received by the International Bureau on 8 September 1999 (08.09.99); new claims 13-17 added; remaining claims unchanged (1 page)]
13. The use of SCH 39166 in combination with an anti-obesity compound for the preparation of a medicament to reduce food cravings in a mammal.
14. The use of claim 13 wherein the anti-obesity compound is selected from beta 3 agonists, sibutramine, lipase inhibitors, NPY agonists and antagonists, 5HT-2C receptor agonists, glucagoπ-li e peptide 1 , melanocortin peptides, cholecystokinin, corticotrophin releasing factor, leptin mimicking compounds and blockers, fat absorption blockers and nicotine agonists.
15. The use of claim 14 wherein the lipase inhibitor is oπϊstat
16. The use of claim 14 wherein the anti-obesHy compound is sibutramine.
17. The use of claim 14 wherein the anti-obesity compound is a beta 3 agonist.
PCT/US1998/022255 1997-10-28 1998-10-26 Method of reducing craving in mammals WO1999021540A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2000517699A JP2001520989A (en) 1997-10-28 1998-10-26 Methods for reducing cravings in mammals
AU11100/99A AU1110099A (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals
BR9814830-3A BR9814830A (en) 1997-10-28 1998-10-26 Desire reduction method in mammals
EP98953826A EP1043980A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals
CA002308453A CA2308453A1 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals
HU0100115A HUP0100115A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals
SK581-2000A SK5812000A3 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals
IL13565998A IL135659A0 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals
KR1020007004505A KR20010031470A (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals
NO20002149A NO20002149L (en) 1997-10-28 2000-04-27 Procedure for reducing mammalian addiction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28
US08/959,213 1997-10-28

Publications (3)

Publication Number Publication Date
WO1999021540A2 WO1999021540A2 (en) 1999-05-06
WO1999021540A3 WO1999021540A3 (en) 1999-09-02
WO1999021540B1 true WO1999021540B1 (en) 1999-10-28

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022255 WO1999021540A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Country Status (16)

Country Link
EP (1) EP1043980A2 (en)
JP (1) JP2001520989A (en)
KR (1) KR20010031470A (en)
CN (1) CN1283116A (en)
AR (1) AR015984A1 (en)
AU (1) AU1110099A (en)
BR (1) BR9814830A (en)
CA (1) CA2308453A1 (en)
CO (1) CO4970824A1 (en)
HU (1) HUP0100115A2 (en)
IL (1) IL135659A0 (en)
NO (1) NO20002149L (en)
PE (1) PE122299A1 (en)
SK (1) SK5812000A3 (en)
WO (1) WO1999021540A2 (en)
ZA (1) ZA989786B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
CA2463987C (en) 2001-11-05 2011-03-08 Seth Lederman Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
EP3170499A1 (en) 2010-09-01 2017-05-24 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
KR20150029713A (en) 2012-07-12 2015-03-18 사이아돈 파마슈티컬스, 인코포레이티드 Fused benzazepines for treatment of tourette's syndrome
US9949983B2 (en) 2013-10-18 2018-04-24 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of stuttering
CN110327350B (en) * 2019-07-11 2021-02-23 温州医科大学 Application of dopamine D1 receptor antagonist SCH39166 in preparation of drugs for treating pathological angiogenesis of eyes
CN110833621A (en) * 2019-12-06 2020-02-25 中国医科大学 Application of dopamine receptor 1 antagonist in preparation of drug for treating mouse schizophrenia caused by ketamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) * 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Also Published As

Publication number Publication date
CO4970824A1 (en) 2000-11-07
IL135659A0 (en) 2001-05-20
HUP0100115A2 (en) 2001-06-28
KR20010031470A (en) 2001-04-16
BR9814830A (en) 2000-10-03
PE122299A1 (en) 1999-12-04
WO1999021540A2 (en) 1999-05-06
EP1043980A2 (en) 2000-10-18
AR015984A1 (en) 2001-05-30
CA2308453A1 (en) 1999-05-06
WO1999021540A3 (en) 1999-09-02
SK5812000A3 (en) 2000-12-11
JP2001520989A (en) 2001-11-06
NO20002149L (en) 2000-06-26
AU1110099A (en) 1999-05-17
NO20002149D0 (en) 2000-04-27
ZA989786B (en) 1999-04-28
CN1283116A (en) 2001-02-07

Similar Documents

Publication Publication Date Title
WO1999021540B1 (en) Method of reducing craving in mammals
Cicero et al. Endogenous opioids participate in the regulation of the hypothalamic-pituitary-luteinizing hormone axis and testosterone's negative feedback control of luteinizing hormone
Codd et al. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites
Epelbaum et al. Characterization, regional distribution, and subcellular distribution of 125I‐Tyr1‐somatostatin binding sites in rat brain
Hammonds Jr et al. beta-endorphin-(1-27) is an antagonist of beta-endorphin analgesia.
Watson et al. [alpha]-MSH in rat brain: occurence within and outside of [beta]-endorphin neurons
ME00527B (en) Opioid agonist/antagonist combinations
Mueller Attenuated pituitary β-endorphin release in estrogen-treated rats
Massicotte et al. An LHRH agonist inhibits FSH-induced cyclic AMP accumulation and steroidogenesis in porcine granulosa cells in culture
FARAH JR et al. Dopaminergic inhibition of pituitary β-endorphin-like immunoreactivity secretion in the rat
Ferrara et al. β-Endorphin: Characteristics of binding sites in the rat brain
EP1040831A3 (en) Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
Davis et al. Relationship between plasma concentrations of immunoreactive beta-endorphin and food intake in rats
ATE414515T1 (en) MEDICATIONS FOR SIMULTANEOUSLY INCREASE ANALGESIC EFFECTIVENESS AND REDUCING DEPENDENCY POTENTIAL CAUSED BY EXOGENE AND ENDOGENE OPIOID AGONISTS
WO1996015148A3 (en) Low molecular weight peptidomimetic growth hormone secretagogues
UA41311C2 (en) Condensed indole DERIVATIVES as receptor 5HT4 antagonists, a pharmaceutical composition
Pavlou et al. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men
CA2325739A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
GT199700037A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RHINITIS
EP0981360A4 (en) Method for preventing gastritis using amylin or amylin agonists
Fuller et al. The effect of quipazine, a serotonin receptor agonist, on serum corticosterone concentration in rats
WO1999024023A3 (en) FORMULATION OF A COMBINATION COMPRISED OF OPIOID AND α - ADRENERGIC AGONISTS AND THE APPLICATION THEREOF
Samson et al. Naloxone-induced dissociation of oxytocin and prolactin releases
PATEL et al. Cysteamine induces a loss of tissue somatostatin-28 when measured as somatostatin-28 (15–28)-like immunoreactivity but not when assessed as somatostatin-28 (1–14)-like immunoreactivity: evidence for the importance of the disulfide bond for cysteamine action
WO2000009537A3 (en) Compounds having growth hormone releasing activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135659

Country of ref document: IL

Ref document number: 98812730.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 504048

Country of ref document: NZ

Ref document number: PV2000-1387

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 5812000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2308453

Country of ref document: CA

Ref document number: 2308453

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007004505

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/004135

Country of ref document: MX

Ref document number: 11100/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 517699

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998953826

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2000-1387

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998953826

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007004505

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-1387

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1998953826

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007004505

Country of ref document: KR